California State Teachers Retirement System Has $4.41 Million Stock Holdings in iRhythm Technologies $IRTC

California State Teachers Retirement System increased its position in iRhythm Technologies (NASDAQ:IRTC) by 22.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,324 shares of the company’s stock after buying an additional 6,763 shares during the period. California State Teachers Retirement System’s holdings in iRhythm Technologies were worth $4,405,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Measured Wealth Private Client Group LLC bought a new position in iRhythm Technologies in the 3rd quarter valued at about $30,000. Employees Retirement System of Texas purchased a new position in shares of iRhythm Technologies during the 3rd quarter valued at $36,000. Torren Management LLC purchased a new stake in iRhythm Technologies during the fourth quarter valued at about $53,000. Smartleaf Asset Management LLC boosted its position in iRhythm Technologies by 63.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 323 shares of the company’s stock worth $58,000 after purchasing an additional 125 shares during the period. Finally, Harvest Fund Management Co. Ltd bought a new position in iRhythm Technologies during the third quarter worth about $69,000.

Insider Buying and Selling

In other iRhythm Technologies news, Director Abhijit Y. Talwalkar purchased 5,312 shares of iRhythm Technologies stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $10.71 per share, for a total transaction of $56,891.52. Following the completion of the transaction, the director owned 25,611 shares of the company’s stock, valued at approximately $274,293.81. This trade represents a 26.17% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.98% of the company’s stock.

iRhythm Technologies Trading Down 0.2%

NASDAQ:IRTC opened at $127.84 on Friday. iRhythm Technologies has a 12 month low of $100.85 and a 12 month high of $212.00. The company has a 50 day simple moving average of $115.03 and a two-hundred day simple moving average of $124.57. The company has a current ratio of 5.17, a quick ratio of 4.98 and a debt-to-equity ratio of 4.03. The company has a market cap of $4.20 billion, a PE ratio of -297.30 and a beta of 1.30.

iRhythm Technologies (NASDAQ:IRTC) last released its earnings results on Thursday, August 6th. The company reported $0.58 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.62. iRhythm Technologies had a positive return on equity of 10.81% and a negative net margin of 1.69%.The company had revenue of $224.17 million for the quarter, compared to the consensus estimate of $219.30 million. During the same period in the previous year, the business earned ($0.32) earnings per share. iRhythm Technologies’s quarterly revenue was up 20.1% compared to the same quarter last year. Research analysts forecast that iRhythm Technologies will post 0.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on IRTC shares. Citigroup lifted their price objective on shares of iRhythm Technologies from $155.00 to $157.00 and gave the company a “buy” rating in a research note on Monday, May 4th. HC Wainwright reiterated a “buy” rating on shares of iRhythm Technologies in a research note on Monday, June 1st. Truist Financial lowered their price objective on shares of iRhythm Technologies from $174.00 to $160.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Needham & Company LLC lowered their price target on shares of iRhythm Technologies from $255.00 to $192.00 and set a “buy” rating for the company in a research note on Friday. Finally, Stephens assumed coverage on iRhythm Technologies in a research note on Thursday, July 23rd. They set an “overweight” rating and a $160.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, iRhythm Technologies currently has an average rating of “Moderate Buy” and an average target price of $179.36.

More iRhythm Technologies News

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Strong Q2 results: iRhythm reported adjusted earnings of $0.58 per share, versus the consensus estimate of a $0.04 loss, while revenue rose 20.1% year over year to $224.17 million, exceeding the $219.30 million estimate. iRhythm Holdings Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: VitalConnect acquisition expands addressable market: The company agreed to acquire privately held VitalConnect for $287.5 million. The deal would add wearable biosensors and broaden iRhythm’s cardiac-monitoring platform across ambulatory, inpatient and hospital-to-home settings, with closing expected by year-end. iRhythm to Buy VitalConnect for $287.5 Million
• Positive Sentiment: Raised financial ambitions: iRhythm projected 2026 revenue of $880 million to $890 million and is targeting a 13% to 14% adjusted EBITDA margin, signaling confidence in continued growth and operating leverage. iRhythm Outlines 2026 Revenue Outlook
• Neutral Sentiment: Legal overhang may be reduced: A federal court approved a proposed class-action settlement involving purchasers of iRhythm common stock. The settlement could reduce litigation uncertainty, although the articles do not specify its financial impact. Proposed iRhythm Class-Action Settlement
• Negative Sentiment: Lower valuation support from Wells Fargo: Wells Fargo reduced its price target from $180 to $168, though it maintained an “overweight” rating and still implied substantial upside. The cut may have contributed to near-term caution.

iRhythm Technologies Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.